Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT)

2seventy bio (NASDAQ:TSVT)‘s stock had its “sell (e+)” rating restated by research analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

2seventy bio Price Performance

2seventy bio stock traded up $0.17 during trading hours on Friday, hitting $2.61. The company had a trading volume of 380,020 shares, compared to its average volume of 398,038. The firm has a market capitalization of $134.65 million, a P/E ratio of -1.40 and a beta of 1.76. 2seventy bio has a fifty-two week low of $2.35 and a fifty-two week high of $6.40. The firm’s fifty day moving average is $3.28 and its 200-day moving average is $4.15.

Hedge Funds Weigh In On 2seventy bio

Large investors have recently bought and sold shares of the stock. Western Standard LLC bought a new position in shares of 2seventy bio during the 3rd quarter worth about $1,350,000. Marshall Wace LLP increased its stake in 2seventy bio by 50.4% during the second quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after acquiring an additional 223,408 shares during the period. BBR Partners LLC raised its holdings in 2seventy bio by 620.0% in the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after acquiring an additional 155,000 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in 2seventy bio in the 2nd quarter valued at approximately $385,000. Finally, Susquehanna Fundamental Investments LLC lifted its position in shares of 2seventy bio by 39.1% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock worth $740,000 after acquiring an additional 54,076 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.